Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
0.78% $1.300
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 226.02 mill |
EPS: | -0.570 |
P/E: | -2.28 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 173.86 mill |
Avg Daily Volume: | 2.03 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -2.28 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.39x |
Company: PE -2.28 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.169 (-86.98%) $-1.131 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 1.199 - 1.401 ( +/- 7.77%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Tucker Sean | Buy | 90 000 | Common Stock |
2024-03-18 | Tucker Sean | Buy | 410 000 | Stock Option (right to buy) |
2023-03-28 | Tucker Sean | Sell | 3 683 | Common Stock |
2023-12-08 | Tucker Sean | Sell | 34 288 | Common Stock |
2024-02-02 | Tucker Sean | Sell | 9 220 | Common Stock |
INSIDER POWER |
---|
94.84 |
Last 96 transactions |
Buy: 11 481 431 | Sell: 272 611 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.300 (0.78% ) |
Volume | 2.78 mill |
Avg. Vol. | 2.03 mill |
% of Avg. Vol | 136.67 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:33 | buy | $1.200 | N/A | Active |
---|
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.